Stockreport

Sage Therapeutics Announces Topline Results from the Phase 2 DIMENSION Study of Dalzanemdor (SAGE-718) in the Treatment of Cognitive Impairment Associated with Huntington's Disease [Yahoo!...

Sage Therapeutics, Inc.  (SAGE) 
Last sage therapeutics, inc. earnings: 2/27 06:30 am Check Earnings Report
US:NASDAQ Investor Relations: investor.sagerx.com/investor-relations
PDF Based on these data, the Company does not plan further development of dalzanemdor CAMBRIDGE, Mass., November 20, 2024 BUSINESS WIRE )--Sage Therapeutics, Inc. (Nasdaq [Read more]